The Early History of Arimoclomol for Inclusion Body Myositis

Authors

  • Mazen M. Dimachkie, M.D.
  • Pedro M. Machado
  • Claus Sundgreen
  • Thomas Blaettler
  • Jeffery Statland
  • Andrew Heim
  • Laura Herbelin
  • Linda Greensmith
  • Michael G. Hanna
  • Richard J. Barohn, M.D. University of Missouri, Columbia, MO

DOI:

https://doi.org/10.17161/rrnmf.v2i2.15404

Metrics

Metrics Loading ...

Downloads

Download data is not yet available.

References

Cudkowicz ME, Shefner JM, Simpson E, Grasso D, Yu H, Zhang H, Shui A, Schoenfeld D, Brown RH, Wieland S, Barber JR; Northeast ALS Consortium. Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis. Muscle Nerve. 2008;38(1):837-44. doi: 10.1002/mus.21059. PMID: 18551622.

Kieran D, Kalmar B, Dick JR, Riddoch-Contreras J, Burnstock G, Greensmith L. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med. 2004;10(4):402-5. doi: 10.1038/nm1021. Epub 2004 Mar 21. PMID: 15034571.

Ahmed M, Machado PM, Miller A, Spicer C, Herbelin L, He J, Noel J, Wang Y, McVey AL, Pasnoor M, Gallagher P, Statland J, Lu CH, Kalmar B, Brady S, Sethi H, Samandouras G, Parton M, Holton JL, Weston A, Collinson L, Taylor JP, Schiavo G, Hanna MG, Barohn RJ, Dimachkie MM, Greensmith L. Targeting protein homeostasis in sporadic inclusion body myositis. Sci Transl Med. 2016;8(331):331ra41. doi: 10.1126/scitranslmed.aad4583. PMID: 27009270; PMCID: PMC5043094.

Jackson CE, Barohn RJ, Gronseth G, Pandya S, Herbelin L; Muscle Study Group. Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity. Muscle Nerve. 2008;37(4):473-6. doi: 10.1002/mus.20958. PMID: 18236463.

Study of Arimoclomol in Inclusion Body Myositis. Trial details publicly available at: https://clinicaltrials.gov/ct2/show/NCT02753530

Downloads

Published

2021-05-27

Issue

Vol. 2 No. 2 (2021)

Section

Looking Back and Looking Forward at Stuff (Reviews)

License

Copyright (c) 2021 Mazen M. Dimachkie, Pedro M. Machado , Claus Sundgreen, Thomas Blaettler, Jeffery Statland, Andrew Heim, Linda Greensmith , Michael G. Hanna, Richard J. Barohn

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

How to Cite

Dimachkie, M. ., Machado, P., Sundgreen, C. ., Blaettler, T. ., Statland, J. ., Heim, A. ., Herbelin, L., Greensmith, L. ., Hanna, M. ., & Barohn, R. J. (2021). The Early History of Arimoclomol for Inclusion Body Myositis. RRNMF Neuromuscular Journal, 2(2), 62-70. https://doi.org/10.17161/rrnmf.v2i2.15404